A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence

References

• Aliyev, N. A., & Aliyev, Z. N. (2005). Application of glycine in acute alcohol hallucinosis. Human Psychopharmacology: Clinical and Experimental, 20(8), 591–594. doi: 10.1002/hup.735
   PubMed Web of Science ®Google Scholar
• Anton, R. F., Moak, D. H., & Latham, P. K. (1996). The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Archives of General Psychiatry, 53(3), 225–231. doi:10.1001/archpsyc.1996.01830030047008
   PubMed Web of Science ®Google Scholar
• Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., … Carpenter, W. T. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry, 164(10), 1593–1602. doi: 10.1176/appi.ajp.2007.06081358
   PubMed Web of Science ®Google Scholar
• Cioffi, C. L., & Guzzo, P. R. (2016). Inhibitors of glycine transporter-1: Potential therapeutics for the treatment of CNS disorders. Current Topics in Medicinal Chemistry, 16(29), 3404–3437. doi: 10.2174/1568026616666160405113340
   PubMed Web of Science ®Google Scholar
• Coyle, J. T. (2006). Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms. Neurotoxicity Research, 10(3-4), 221–233. doi:10.1007/BF03033359
   PubMed Web of Science ®Google Scholar
• Coyle, J. T., Tsai, G., & Goff, D. C. (2002). Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Current Drug Target -CNS & Neurological Disorders, 1(2), 183–189. doi:10.2174/1568007024606212
   PubMedGoogle Scholar
• D'Souza DC, B. A., Zimmerman, L., Tracy, L., Larvae, K., Capsule, K., & Krystal, J. H. (1997). Glycine ketamine interactions in healthy humans. Proceedings of the 36th Annual Meeting American College of Neuropsychopharmacology. Kona, HI (abstract) 286.
   Google Scholar
• D'Souza, D. C., Charney, D. S., & Krystal, J. H. (1995). Glycine site agonists of the NMDA receptor: A review. CNS Drug Reviews, 1, 227–260. doi:10.1111/j.1527-3458.1995.tb00285.x
   Google Scholar
• De Bejczy, A., Nations, K. R., Szegedi, A., Schoemaker, J., Ruwe, F., & Soderpalm, B. (2014). Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: A randomized, double-blind, placebo-controlled trial. Alcoholism: Clinical and Experimental Research, 38(9), 2427–2435. doi:10.1111/acer.12501
   PubMed Web of Science ®Google Scholar
• Diaz, P., Bhaskara, S., Dursun, S. M., & Deakin, B. (2005). Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. Journal of Clinical Psychopharmacology, 25(3), 277–278. doi:10.1097/01.jcp.0000165740.22377.6d
   PubMed Web of Science ®Google Scholar
• Dickerson, D., Pittman, B., Ralevski, E., Perrino, A., Limoncelli, D., Edgecombe, J., … Petrakis, I. (2010). Ethanol-like effects of thiopental and ketamine in healthy humans. Journal of Psychopharmacology, 24(2), 203–211. doi:10.1177/0269881108098612
   PubMed Web of Science ®Google Scholar
• Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & Goff, D. C. (2000). Placebo-controlled trial of glycine added to clozapine in schizophrenia. American Journal of Psychiatry, 157(5), 826–828. doi:10.1176/appi.ajp.157.5.826
   PubMed Web of Science ®Google Scholar
• Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003). The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychotherapy and Psychosomatics, 72(3), 115–127. doi:10.1159/000069738
   PubMed Web of Science ®Google Scholar
• Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., & McGuire, P. (2015). Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebo-controlled trials. Schizophrenia Bulletin, 41(4), 892–899. doi:10.1093/schbul/sbu170
   PubMed Web of Science ®Google Scholar
• Harvey, R. J., & Yee, B. K. (2013). Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nature Reviews Drug Discovery, 12(11), 866–885. doi:10.1038/nrd3893
   PubMed Web of Science ®Google Scholar
• Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996). Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry, 169(05), 610–617. doi:10.1192/bjp.169.5.610
   PubMedGoogle Scholar
• Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry, 56(1), 29–36. doi:10.1001/archpsyc.56.1.29
   PubMed Web of Science ®Google Scholar
• Heresco-Levy, U., Silipo, G., & Javitt, D. C. (1996). Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacology Bulletin, 32(4), 731–740.
   PubMedGoogle Scholar
• Javitt, D. C., Balla, A., Burch, S., Suckow, R., Xie, S., & Sershen, H. (2004). Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology, 29(2), 300–307. doi:10.1038/sj.npp.1300313
   PubMed Web of Science ®Google Scholar
• Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., … Garbutt, J. C. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. Journal of the American Medical Association, 311(18), 1889–1900. doi:10.1001/jama.2014.3628
   PubMed Web of Science ®Google Scholar
• Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008). NMDA receptors in clinical neurology: Excitatory times ahead. Lancet Neurology, 7(8), 742–755. doi:10.1016/S1474-4422(08)70165-0
   PubMed Web of Science ®Google Scholar
• Kingsbury, S. J., & Salzman, C. (1990). Disulfiram in the treatment of alcoholic patients with schizophrenia. Psychiatric Services, 41(2), 133–134. doi:10.1176/ps.41.2.133
   Google Scholar
• Krystal, J. H., D'Souza, D. C., Madonick, S., & Petrakis, I. L. (1999). Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research, 35(Suppl), S35–S49. doi:10.1016/S0920-9964(98)00162-5
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., Petrakis, I. L., Limoncelli, D., Webb, E., Gueorgueva, R., D'Souza, D. C., … Charney, D. S. (2003). Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology, 28(11), 2020–2028. doi:10.1038/sj.npp.1300252
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., Petrakis, I. L., Webb, E., Cooney, N. L., Karper, L. P., Namanworth, S., … Charney, D. S. (1998). Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Archives of General Psychiatry, 55(4), 354–360. doi: 10.1001/archpsyc.55.4.354
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., Petrakis, I. L., Limoncelli, D., Nappi, S. K., Trevisan, L., Pittman, B., & D'Souza, D. C. (2011). Characterization of the interactive effects of glycine and D-cycloserine in men: Further evidence for enhanced NMDA receptor function associated with human alcohol dependence. Neuropsychopharmacology, 36(3), 701–710. doi:10.1038/npp.2010.203
   PubMed Web of Science ®Google Scholar
• Lido, H. H., Ericson, M., Marston, H., & Soderpalm, B. (2011). A role for accumbal glycine receptors in modulation of dopamine release by the glycine transporter-1 inhibitor Org25935. Frontiers in Psychiatry, 2, 8. doi: 10.3389/fpsyt.2011.00008
   PubMedGoogle Scholar
• Lido, H. H., Marston, H., Ericson, M., & Soderpalm, B. (2012). The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. Addiction Biology, 17(5), 897–907. doi:10.1111/j.1369-1600.2011.00367.x
   PubMed Web of Science ®Google Scholar
• Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005). Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry, 10(1), 79–104. doi:10.1038/sj.mp.4001556
   PubMed Web of Science ®Google Scholar
• Molander, A., Lido, H. H., Lof, E., Ericson, M., & Soderpalm, B. (2006). The glycine reuptake inhibitor Org 25935 decreases ethanol intake and preference in male wistar rats. Alcohol and Alcoholism, 42(1), 11–18. doi:10.1093/alcalc/agl085
   PubMed Web of Science ®Google Scholar
• Petrakis, I. L., O’Malley, S., Rounsaville, B., Poling, J., McHugh-Strong, C., & Krystal, J. H. (2004). Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology, 172(3), 291–297. doi:10.1007/s00213-003-1658-9
   PubMed Web of Science ®Google Scholar
• Petrakis, I. L., Poling, J., Levinson, C., Nich, C., Carroll, K., & Rounsaville, B., & VA New England VISN I MIRECC Study Group. (2005). Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biological Psychiatry, 57(10), 1128–1137. doi:10.1016/j.biopsych.2005.02.016
   PubMed Web of Science ®Google Scholar
• Ralevski, E., O’Brien, E., Jane, J. S., Dwan, R., Dean, E., Edens, E., … Petrakis, I. (2011). Treatment with acamprosate in patients with schizophrenia spectrum disorders and comorbid alcohol dependence. Journal of Dual Diagnosis, 7(1-2), 64–73. doi:10.1080/15504263.2011.569440
   PubMed Web of Science ®Google Scholar
• Regier, D. A., Farmer, M. E., & Rae, D. S. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA) study. Journal of the American Medical Association, 264(19), 2511–2518. doi:10.1001/jama.1990.03450190043026
   PubMed Web of Science ®Google Scholar
• Soderpalm, B., & Ericson, M. (2013). Neurocircuitry involved in the development of alcohol addiction: The dopamine system and its access points. Current Topics in Behavioral Neurosciences, 13, 127–161. doi: 10.1007/978-3-642-28720-6_170
   PubMedGoogle Scholar
• Soderpalm, B., Lido, H. H., & Ericson, M. (2017). The glycine receptor-A functionally important primary brain target of ethanol. Alcoholism Clinical and Experimental Research, 41(11), 1816–1830. doi: 10.1111/acer.13483
   PubMed Web of Science ®Google Scholar
• Tsai, G. E., & Lin, P. Y. (2010). Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia: A critical review and meta-analysis. Current Pharmaceutical Design, 16(5), 522–537. doi:10.2174/138161210790361452
   PubMed Web of Science ®Google Scholar
• Vengeliene, V., Leonardi-Essmann, F., Sommer, W. H., Marston, H. M., & Spanagel, R. (2010). Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats. Biological Psychiatry, 68(8), 704–711. doi:10.1016/j.biopsych.2010.05.029
   PubMed Web of Science ®Google Scholar
• Woods, S. W., Walsh, B. C., Hawkins, K. A., Miller, T. J., Saksa, J. R., D'Souza, D. C., … Krystal, J. H. (2013). Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology, 23(8), 931–940. doi:10.1016/j.euroneuro.2012.09.008
   PubMed Web of Science ®Google Scholar
• Yang, C. R., & Svensson, K. A. (2008). Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: The therapeutic potentials for schizophrenia. Pharmacology and Therapeutics, 120(3), 317–332. doi:10.1016/j.pharmthera.2008.08.004
   PubMed Web of Science ®Google Scholar